Cargando…
Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report
INTRODUCTION: Pembrolizumab and other immune checkpoint inhibitors are the emerging treatment for selected, high-grade malignancies. However, a small number of patients are unable to tolerate its adverse effects, leading to discontinuation of this potentially life-changing therapy. In this study, we...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086081/ https://www.ncbi.nlm.nih.gov/pubmed/33926558 http://dx.doi.org/10.1186/s13256-021-02722-8 |